The board of directors of Ocumension Therapeutics announce that the Group has recently initiated the real world study of its core product, OT-401 (YUTIQ) in Boao Super Hospital in Hainan province, China, and is recruiting patients simultaneously in various ophthalmic clinical centers across the country. At the same time, a phase III clinical study of OT-401 evaluating the safety and efficacy of fluocinolone vitreous implants in patients with chronic non-infectious uveitis affecting the posterior segment of the eye is also underway in various ophthalmic clinical centers across the country. The real world study data of OT-401 are expected to provide support and supplement to the phase III clinical trial data of OT-401. The real-world study, a more cost-effective and less time-consuming supplement to the traditional clinical trial, aims to form clinical evidence in relation to the use and potential benefits or risks of medical products by analysing the patient-related data collected in a real-world environment. The initiation of the real world study of OT-401 is expected to accelerate the new drug application registration in China. OT-401 (YUTIQ), the core product of the Company, is a first-in-class, innovative injectable, sustained-release micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. OT-401 is a sterile non-bioerodible intravitreal implant designed to provide sustained release of a total of 0.18 mg of the active ingredient fluocinolone acetonide, a corticosteroid, at a controlled rate for up to 36 months from a single administration performed in an outpatient visit. To date, YUTIQ is the first and only uveitis treatment designed to deliver fluocinolone for up to 36 months that has been approved by the U.S. Food and Drug Administration.